Inhibrx (NASDAQ:INBX – Get Free Report) released its earnings results on Monday. The company reported ($3.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.88) by ($0.21), Zacks reports. The company had revenue of $0.10 million for the quarter.
Inhibrx Trading Down 1.1 %
Inhibrx stock opened at $13.94 on Tuesday. Inhibrx has a 1 year low of $10.80 and a 1 year high of $35.42. The firm’s 50 day moving average price is $13.33 and its 200-day moving average price is $14.67.
Wall Street Analysts Forecast Growth
Separately, JMP Securities restated a “market perform” rating on shares of Inhibrx in a research report on Wednesday, January 22nd.
About Inhibrx
Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.
See Also
- Five stocks we like better than Inhibrx
- Are Penny Stocks a Good Fit for Your Portfolio?
- Kohl’s Posts Another Kitchen Sink Quarter, But New CEO Has a Plan
- Investing in Travel Stocks Benefits
- Southwest Airlines Could Triple From Here—Here’s How
- What Are Some of the Best Large-Cap Stocks to Buy?
- Salesforce: An Early AI Opportunity With Long-Term Potential
Receive News & Ratings for Inhibrx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibrx and related companies with MarketBeat.com's FREE daily email newsletter.
